Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
Jean-Sébastien FrenelA LusqueSuzette DelalogeJ-M FerreroThomas BachelotI DesmoulinsC LevyJ-C EymardA GonçalvesAnne PatsourisM A Mouret ReynierM J-C TheryT PetitLuc CabelL UwerM DebledM ChevrotA MailliezWilliam JacotT de La Motte RougePublished in: British journal of cancer (2023)
In this large cohort of HR+/HER2- MBC patients treated in a pre-CDK4/6 inhibitors era, gBRCAm status was associated with a lower OS and lower PFS following first-line endocrine therapy, but not following first-line chemotherapy.